ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) from its SEC filings: 2025 revenue $3.7 billion (+65% vs the year before), net margin 8%, free cash flow $465.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $3.7 billion |
| Revenue growth | +65% |
| Net income | $313.7 million |
| Net margin | 8.4% |
| Free cash flow | $465.4 million |
| Diluted EPS | $2.33 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +67% |
| Cash | $1.7 billion |
| Long-term debt | $677.7 million |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.